DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election of Group I (claims 1-17) in the reply filed on July 9, 2026, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Claims 1-20 are pending, of which claims 18-20 are withdrawn as being drawn to a non-elected invention. The restriction requirement is still deemed proper and therefor made FINAL. Pending claims 1-17 have been examined on the merits.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as failing to set forth the subject matter which the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the applicant regards as the invention.
In claim 4, the claim recites at line 1 the phrase “numerical values”; however, it is unclear what numbers, values, and what basis thereof are intended by the phrasing. Clarification is required.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-71 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for the processes exemplified (as further detailed below), does not reasonably provide enablement for all microtissues, or all conditions arriving at the desired differentiated microtissues having (vs. embriod bodies (EBs) reduced adhesion and reduced expression of COL6A2, CD44, COL6A1, ANXA1, ANXA2 and/or S100A11 adhesion molecules. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.
The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in Wands states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not ‘experimentation’” (Wands, 8 USPQ2sd 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (Wands, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.
(1) The nature of the invention and (2) the breadth of the claims:
The claims are drawn to a process of producing a microtissue from aggregates of pluripotent stem cells (non-human), and transferring to a bioreactor without matrix adherence in the absence of growth factors (claims 1+) and optionally (claims 3+) differentiating to form cell-types. The claims taken together with the specification imply a breadth greater than supported by the disclosure.
(3) The state of the prior art and (4) the predictability or unpredictability of the art:
The state of the prior art is such that cull culturing, suspensions, matrices, and media therefor, and adhesion molecules were known in the art. For example:
WO 2020/123876 A1 (IDS, of record) teaches known culturing of cells to form microtissues and the conditions specific to such cells (see entire document).
WO 2018/011805 A2 (IDS, of record) teaches (see e.g. fig 1A and abstract) culturing cells in a bioreactor and conditions therefor, and further discusses engineered meat processes (see citations therein at’805 pages 2-3).
However, the processes of the prior art remained highly dependent upon the source cell identity, each process further dependent upon the conditions (culturing, expanding, differentiating, etc.) upon which the cells are subject, and also dependent upon additional conditions specific to each pathway for each product cell type (and intermediates therealong) to obtain a resultant cell. The routes of each may be mapped individually for each cell type (or retroactively described in order to clarify the process for obtaining a particular cell type and adhesion expression identity), however, the predictive pathway for the genus of “cell types of interest” and “microtissues” per se, sourcing from any non-human “stem cell”, and merely stating the desired expression in a desired product was not recognized in the art, especially for the myriad of processes as instant embraced by the claims.
Since the process of the generic “producing a microtissue” as claimed remains largely unsolved, means for producing such tissue is highly unpredictable.
(5) The relative skill of those in the art:
The relative skill of those in the art is high. However the process as instantly claimed for the scope thereof, remained beyond the purview of one of skill in the art at the time of the instant invention effective filing.
Accordingly, one would have turned to the instant disclosure for additional direction and guidance.
(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:
The specification has provided limited guidance for a finite number of non-human source cells, a finite number of steps and conditions correlated to each cell and intermediate in the processes, and a finite number of product microtissues, including the adhesion characterization of the product microtissues after so obtaining. However, the specification does not provide a generic process for all cells, all conditions, and all possible resultant tissues, for the broad and variable genus, as instantly claimed.
(8) The quantity of experimentation necessary:
Considering the state of the art and the high unpredictability and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention for the scope instantly claimed.
It is the Examiner’s position that one skilled in the art could not practice the invention commensurate in the scope of the claims without undue experimentation.
Conclusion
No claims are presently allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AARON J KOSAR whose telephone number is (571)270-3054. The examiner can normally be reached Mon.-Fri. 9-6 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/AARON J KOSAR/ Primary Examiner, Art Unit 1655